Physician profile
John C Nicholson
NPI 1497723795
$6,603.41
in general payments reported to CMS, 2019-2025
36 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $963 · 2021: $1,122 · 2022: $1,345 · 2023: $1,444 · 2024: $600 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $805.98 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $794.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $787.25 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $704.86 | 2019-2024 | |
| Amgen INC. | $491.27 | 2019-2025 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.03 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $421.67 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $326.23 | 2021-2025 | |
| Mylan Specialty L.P. | $325.03 | 2019-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $209.10 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $158.81 | 2019-2023 | |
| Glaxosmithkline, LLC. | $157.40 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $132.79 | 2021-2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $110.58 | 2023 | Inspire |
| Xeris Pharmaceuticals, INC. | $77.30 | 2022-2023 | Gvoke Hypopen |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $75.91 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $64.41 | 2020-2021 | |
| Amarin Pharma, INC. | $62.10 | 2019-2021 | |
| Daiichi Sankyo INC. | $48.33 | 2022 | |
| Abiomed | $42.74 | 2024 | Impella |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.29 | 2025 | Caplyta |
| Viatris Specialty LLC | $36.83 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $36.37 | 2019-2020 | |
| Abbvie INC. | $31.45 | 2021 | |
| Averitas Pharma INC. | $27.20 | 2024 | Qutenza |
| Zyla Life Sciences, INC. | $25.78 | 2019 | |
| Sanofi Pasteur INC. | $23.77 | 2019 | |
| Idorsia Pharmaceuticals US INC | $21.90 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $20.20 | 2019 | |
| Irhythm Technologies, INC. | $19.42 | 2024 | Zio Monitor, Zio Xt Patch |
| Actelion Pharmaceuticals US, INC. | $18.78 | 2025 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $14.67 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.05 | 2019 | |
| Shield Therapeutics INC | $13.85 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $11.70 | 2021 | |
| Genentech USA, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.